



GAU 1614
RECEIVED

NOV 17 1999

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	J. Pineiro, et al.		
Serial No.:	09/392,406	Case No.:	T1427
Filed:	September 9, 1999		
For:	INDOLE AND INDOLINE DERIVATIVES AS 5-HT6 SELECTIVE LIGANDS		

Art Unit:
1614

Examiner:

#3
HKO
11/18/99

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


The citations listed on enclosed Form PTO-1449 are being submitted under the provisions of 37 CFR 1.56 and 1.97 in order to comply with the Applicants' duty of disclosure. Their inclusion herein shall not be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of the cited documents, except for the pending patent application, are included herewith.

Applicants submit that the references listed on Form PTO-1449 taken alone or in any reasonable combination neither anticipate nor render obvious the present invention. It is respectfully requested that the Examiner initial and return the enclosed copy of Form PTO-1449 to evidence consideration of the disclosed references.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231,
on the date appearing below.

MERCK & CO., INC.


By 

Date: Nov 10, 1999

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ in that this reference is being submitted prior to the mailing of the first Action on the merits, no fee is due.
- ☐ in that this reference is being submitted prior to the Examination of the application, no additional fee is required.
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.
- ☐ further to Information Disclosure Rule 97(c) applicants authorize payment of the fee set forth under 1.17(p). The fee may be taken from Merck Deposit Account No. 13-2755.

The Examiner is invited to contact the attorney for applicant at the telephone number provided below if such would advance the prosecution of this application or if the Examiner has any questions regarding this Information Disclosure Statement. Applicants respectfully request early examination and Notice of Allowance.

Respectfully submitted,

By 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: November 10, 1999